Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
T

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achieve CR, MRD- Patients Have Better Survival, Many MRD Related Specifics Need to Be Defined

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Thomas Martin
November 18, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
2nd SOHO Italian Conference

2nd SOHO Italian Conference

Tue, Sep 22, 2020
The Asian Oncology Society 1st Virtual International Conference

The Asian Oncology Society 1st Virtual International Conference

Fri, Nov 27, 2020
19:57
Moffitt Cancer Center

Efficacy Analysis of Anti-CD38 in R/R Multiple Myeloma: What Is the Bene...

Feat. K. Shain
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering MM, I...

Feat. K. Shain
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy and...

25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
08:40
Surbhi Sidana

Duration of Complete Response Impacts Overall Survival in Multiple Myeloma

09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
08:25
Cristina Gasparetto

2020 ASCO Update on Selinexor in R/R Multiple Myeloma: What Is the Effec...

15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

09:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal and Ho...

Feat. A. Krishnan